Additionally, tumor heterogeneity and compensatory signaling pathways may limit the efficacy of CXCL12-targeted therapies, necessitating further investigation into combination strategies with other immunotherapies or targeted treatments. The gene discussed is CXCL12; the disease is neoplasm.